Compare AGM & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | ZYME |
|---|---|---|
| Founded | 1987 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | AGM | ZYME |
|---|---|---|
| Price | $182.33 | $25.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $219.00 | $29.50 |
| AVG Volume (30 Days) | 83.2K | ★ 1.7M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 12.85 | N/A |
| EPS | ★ 17.55 | N/A |
| Revenue | ★ $377,946,000.00 | $134,481,000.00 |
| Revenue This Year | $14.80 | $64.45 |
| Revenue Next Year | $9.98 | $67.04 |
| P/E Ratio | $10.38 | ★ N/A |
| Revenue Growth | 8.81 | ★ 116.21 |
| 52 Week Low | $155.00 | $9.03 |
| 52 Week High | $216.35 | $28.49 |
| Indicator | AGM | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 69.06 | 60.22 |
| Support Level | $173.59 | $24.79 |
| Resistance Level | $186.64 | $27.49 |
| Average True Range (ATR) | 4.35 | 1.27 |
| MACD | 1.31 | -0.27 |
| Stochastic Oscillator | 85.65 | 36.74 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.